The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Cost-Benefit Analysis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cost-Benefit Analysis


Psychiatry related information on Cost-Benefit Analysis


High impact information on Cost-Benefit Analysis

  • The table summarizes the potential indications for hematopoietic growth factor use as discussed in this article, as justified by current evidence of benefit, harm, and cost effectiveness resulting from their use in various clinical settings [10].
  • METHODS: We compared the costs and benefits of no preventive intervention (watchful waiting) with those of universal screening or presumptive treatment with 400 mg of albendazole per day for five days [11].
  • Before the widespread use of cholesterol-lowering drugs in such patients is recommended, its cost effectiveness should be demonstrated [3].
  • The cost effectiveness of treatment with accelerated t-PA rather than streptokinase compares favorably with that of other therapies whose added medical benefit for dollars spent is judged by society to be worthwhile [2].
  • The cost effectiveness of estrogen use in postmenopausal women was analyzed with use of data from the medical and epidemiologic literature [12].

Chemical compound and disease context of Cost-Benefit Analysis


Biological context of Cost-Benefit Analysis


Anatomical context of Cost-Benefit Analysis


Associations of Cost-Benefit Analysis with chemical compounds


Gene context of Cost-Benefit Analysis

  • Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2 [32].
  • It could also be the key to demonstrating cost-effectiveness for CYP2D6 genotyping in critical dose drugs [33].
  • It is likely that the cost/benefit ratio of not producing or of producing a defined amount of Hsp70 under stress conditions varies for different cell types and under different physiological conditions and, accordingly, specific regulatory mechanisms operating at the transcriptional and post-transcriptional levels have evolved [34].
  • We studied three genes from the CBF (C-repeat/dehydration responsive element binding factor) cold tolerance pathway, CBF1, 2 and 3, in Arabidopsis thaliana to test for benefits and costs of constitutive cold tolerance [35].
  • The cost-effectiveness ratio for alteplase was most sensitive to assumptions regarding long term survival and cost differences after the first year following treatment [36].

Analytical, diagnostic and therapeutic context of Cost-Benefit Analysis


  1. Adjuvant therapy for colon cancer. Macdonald, J.S. CA: a cancer journal for clinicians. (1997) [Pubmed]
  2. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. Mark, D.B., Hlatky, M.A., Califf, R.M., Naylor, C.D., Lee, K.L., Armstrong, P.W., Barbash, G., White, H., Simoons, M.L., Nelson, C.L. N. Engl. J. Med. (1995) [Pubmed]
  3. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. Johannesson, M., Jönsson, B., Kjekshus, J., Olsson, A.G., Pedersen, T.R., Wedel, H. N. Engl. J. Med. (1997) [Pubmed]
  4. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting. Mansergh, G., Haddix, A.C., Steketee, R.W., Nieburg, P.I., Hu, D.J., Simonds, R.J., Rogers, M. JAMA (1996) [Pubmed]
  5. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. Curry, S.J., Grothaus, L.C., McAfee, T., Pabiniak, C. N. Engl. J. Med. (1998) [Pubmed]
  6. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neumann, P.J., Hermann, R.C., Kuntz, K.M., Araki, S.S., Duff, S.B., Leon, J., Berenbaum, P.A., Goldman, P.A., Williams, L.W., Weinstein, M.C. Neurology (1999) [Pubmed]
  7. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Tunis, S.L., Johnstone, B.M., Gibson, P.J., Loosbrock, D.L., Dulisse, B.K. The Journal of clinical psychiatry. (1999) [Pubmed]
  8. HIV transmission and the cost-effectiveness of methadone maintenance. Zaric, G.S., Barnett, P.G., Brandeau, M.L. American journal of public health. (2000) [Pubmed]
  9. The cost-effectiveness of methadone maintenance as a health care intervention. Barnett, P.G. Addiction (1999) [Pubmed]
  10. Hematopoietic growth factors. Bociek, R.G., Armitage, J.O. CA: a cancer journal for clinicians. (1996) [Pubmed]
  11. The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants. Muennig, P., Pallin, D., Sell, R.L., Chan, M.S. N. Engl. J. Med. (1999) [Pubmed]
  12. Estrogen use in postmenopausal women--costs, risks, and benefits. Weinstein, M.C. N. Engl. J. Med. (1980) [Pubmed]
  13. Cisplatin-based combination chemotherapy in the treatment of advanced-stage testicular cancer: cost-benefit analysis. Shibley, L., Brown, M., Schuttinga, J., Rothenberg, M., Whalen, J. J. Natl. Cancer Inst. (1990) [Pubmed]
  14. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., Tomenson, B. Gastroenterology (2003) [Pubmed]
  15. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Anderson, D.R., O'Brien, B.J., Levine, M.N., Roberts, R., Wells, P.S., Hirsh, J. Ann. Intern. Med. (1993) [Pubmed]
  16. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Owens, D.K., Sanders, G.D., Harris, R.A., McDonald, K.M., Heidenreich, P.A., Dembitzer, A.D., Hlatky, M.A. Ann. Intern. Med. (1997) [Pubmed]
  17. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis. Lightfoot, R.W., Luft, B.J., Rahn, D.W., Steere, A.C., Sigal, L.H., Zoschke, D.C., Gardner, P., Britton, M.C., Kaufman, R.L. Ann. Intern. Med. (1993) [Pubmed]
  18. Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysis. Goverde, A.J., McDonnell, J., Vermeiden, J.P., Schats, R., Rutten, F.F., Schoemaker, J. Lancet (2000) [Pubmed]
  19. Gastroenterologist-administered propofol versus meperidine and midazolam for advanced upper endoscopy: a prospective, randomized trial. Vargo, J.J., Zuccaro, G., Dumot, J.A., Shermock, K.M., Morrow, J.B., Conwell, D.L., Trolli, P.A., Maurer, W.G. Gastroenterology (2002) [Pubmed]
  20. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Kuehne, F.C., Bethe, U., Freedberg, K., Goldie, S.J. Arch. Intern. Med. (2002) [Pubmed]
  21. Cobalamin deficiency in general practice. Assessment of the diagnostic utility and cost-benefit analysis of methylmalonic acid determination in relation to current diagnostic strategies. Hølleland, G., Schneede, J., Ueland, P.M., Lund, P.K., Refsum, H., Sandberg, S. Clin. Chem. (1999) [Pubmed]
  22. Recommendations for vitamin A supplementation. Ross, D.A. J. Nutr. (2002) [Pubmed]
  23. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. Edelson, J.T., Tosteson, A.N., Sax, P. JAMA (1990) [Pubmed]
  24. Exercise tomographic thallium-201 imaging in patients with severe coronary artery disease and normal electrocardiograms. Christian, T.F., Miller, T.D., Bailey, K.R., Gibbons, R.J. Ann. Intern. Med. (1994) [Pubmed]
  25. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. Nichols, C.R., Fox, E.P., Roth, B.J., Williams, S.D., Loehrer, P.J., Einhorn, L.H. J. Clin. Oncol. (1994) [Pubmed]
  26. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Maetzel, A., Ferraz, M.B., Bombardier, C. Arthritis Rheum. (1998) [Pubmed]
  27. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. Weinstein, M.C., Siegel, J.E., Gold, M.R., Kamlet, M.S., Russell, L.B. JAMA (1996) [Pubmed]
  28. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. Gage, B.F., Cardinalli, A.B., Albers, G.W., Owens, D.K. JAMA (1995) [Pubmed]
  29. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. Oster, G., Huse, D.M., Delea, T.E., Colditz, G.A. JAMA (1986) [Pubmed]
  30. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. Friedberg, M., Saffran, B., Stinson, T.J., Nelson, W., Bennett, C.L. JAMA (1999) [Pubmed]
  31. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. Snider, D.E., Caras, G.J., Koplan, J.P. JAMA (1986) [Pubmed]
  32. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. Grann, V.R., Whang, W., Jacobson, J.S., Heitjan, D.F., Antman, K.H., Neugut, A.I. J. Clin. Oncol. (1999) [Pubmed]
  33. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Messner, B., Kissling, W., Leucht, S. Clin. Chem. (2005) [Pubmed]
  34. Tissue- and development-specific induction and turnover of hsp70 transcripts from loci 87A and 87C after heat shock and during recovery in Drosophila melanogaster. Lakhotia, S.C., Prasanth, K.V. J. Exp. Biol. (2002) [Pubmed]
  35. Costs and benefits of cold tolerance in transgenic Arabidopsis thaliana. Jackson, M.W., Stinchcombe, J.R., Korves, T.M., Schmitt, J. Mol. Ecol. (2004) [Pubmed]
  36. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction. Barradell, L.B., Goa, K.L. PharmacoEconomics. (1995) [Pubmed]
  37. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. Mahadevia, P.J., Fleisher, L.A., Frick, K.D., Eng, J., Goodman, S.N., Powe, N.R. JAMA (2003) [Pubmed]
  38. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. Durand-Zaleski, I., Roche, B., Buyse, M., Carlson, R., O'Connell, M.J., Rougier, P., Chang, A.E., Sondak, V.K., Kemeny, M.M., Allen-Mersh, T.G., Fagniez, P.L., Le Bourgeois, J.P., Piedbois, P. J. Natl. Cancer Inst. (1997) [Pubmed]
  39. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. Bayoumi, A.M., Brown, A.D., Garber, A.M. J. Natl. Cancer Inst. (2000) [Pubmed]
  40. The cost-effectiveness of sildenafil. Smith, K.J., Roberts, M.S. Ann. Intern. Med. (2000) [Pubmed]
  41. Exercise thallium-201 scintigraphy in the diagnosis and prognosis of coronary artery disease. Kotler, T.S., Diamond, G.A. Ann. Intern. Med. (1990) [Pubmed]
WikiGenes - Universities